Those authors not only demonstrated that cyclic niraparib in vitro treatment of BRCA1-/- cells gives rise to multiple genetically and functionally heterogeneous PARPi-resistant clones, but that similar clonal heterogeneity was observed in a HGSOC patient’s tumor biopsy resistant to PARPi. Here, BRCA1 is linked to neoplasm.